Semler Scientific, Inc. - SMLR STOCK NEWS

Semler Scientific, a leader in healthcare technology solutions, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13 at 1:30 pm ET. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview and engage in one-on-one calls with investors. A live webcast of the event will be available on the Semler Scientific website under the 'Events and Presentations' section, with an archived version accessible for 90 days post-conference. Semler's flagship product, QuantaFlo®, aids in diagnosing peripheral arterial disease.

Semler Scientific (Nasdaq: SMLR) has announced a $20 million stock repurchase program approved by its board of directors. This program allows the company to buy back shares through various means, with no specified expiration date or minimum purchase requirement. CEO Doug Murphy Chutorian expressed confidence in the company’s financial strength and future prospects. Semler focuses on technology solutions to enhance healthcare, including the FDA-cleared QuantaFlo® product for assessing arterial blood flow.

Semler Scientific (Nasdaq: SMLR) announced a published study in the Journal of Vascular Surgery demonstrating the effectiveness of QuantaFlo® in screening for undetected peripheral artery disease (PAD) among 13,971 Medicare Advantage patients. The study found a 31.6% positive rate for PAD and highlighted significant associated risks, including a 60-70% increased risk of all-cause mortality at one year. The findings advocate for early PAD screening, potentially boosting adoption of QuantaFlo® among healthcare providers, according to CEO Doug Murphy-Chutorian.

Semler Scientific (Nasdaq: SMLR) reported a 37% increase in annual revenues to $53.0 million for 2021, compared to $38.6 million in 2020. Net income rose by 23% to $17.2 million, translating to $2.56 per basic share. However, Q4 revenue dipped 4% year-over-year to $11.5 million, with net income dropping 72% to $1.5 million. Notably, the cost of revenues surged 120% in Q4, reflecting a $1.2 million inventory write-down. Despite these challenges, the company maintains a optimistic outlook for continued profitability and growth.

Semler Scientific (Nasdaq: SMLR) will report its fourth quarter and full year financial results for 2021 on February 28, 2022, after U.S. market close. A conference call hosted by CEO Doug Murphy-Chutorian will occur at 4:30 PM ET the same day, featuring senior executives Andrew Weinstein and Dennis Rosenberg. Participants can pre-register for the call to receive a passcode for immediate access. Semler Scientific specializes in technology solutions for healthcare and offers the FDA-cleared QuantaFlo®, a test to evaluate risks of chronic diseases.

Semler Scientific (SMLR) reported strong financial results for Q3 and nine months ending September 30, 2021. Revenues reached $14.0 million, a 30% increase year-over-year, with a pre-tax net income of $5.3 million, down 6% compared to last year. For the nine months, revenues surged 56% to $41.5 million, with total net income rising 82% to $15.7 million. Despite a sequential decline in fee-per-test revenue attributed to the Delta variant, the company remains profitable and expects ongoing revenue growth. Cash reserves improved to $35.9 million.

Semler Scientific, Inc. (Nasdaq: SMLR) announced it will release its financial results for Q3 and the first nine months of 2021 after U.S. markets close on November 1, 2021. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET, joined by senior finance and marketing executives. Participants can pre-register for the call and access it via phone if unable to register online. Semler specializes in technology solutions for healthcare providers, notably with its FDA-cleared QuantaFlo® product for diagnosing peripheral arterial disease.

Semler Scientific, Inc. (SMLR) announced CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg's participation in several virtual investor conferences in September 2021. The events include the Colliers 2021 Institutional Investor Conference on September 9, H.C. Wainwright & Co. 23rd Annual Global Investment Conference on September 13, and the 2021 Best Ideas Growth (BIG5) Conference on September 14-15. Semler provides technology solutions to enhance healthcare provider effectiveness and offers the QuantaFlo® test for diagnosing peripheral arterial disease.

Semler Scientific (OTCQB: SMLR) reported a significant financial uplift for Q2 and H1 2021. Revenues surged to $14.3 million, marking a 125% increase from $6.4 million year-over-year. Net income also rose sharply by 522% to $6.7 million, with earnings per share reaching $1.00. The company holds $28.5 million in cash and aims for continued profitability and growth in the expanding peripheral arterial disease (PAD) testing market.